Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Analgesics
Cortex Receives Approval from German Regulatory Authority to Proceed with Two Clinical Trials for AMPAKINE(R) CX717 for the Acute Treatment of Respiratory Depression Due to Opiate Analgesics
March 21st, 2008
Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), has received approval from the German Federal Institute For Drugs And Medical Devices (BfArM) to initiate two AMPAKINE(R) CX717 clinical studies. These studies will assess whether the pre-administration of CX717 can prevent the development of respiratory depression (RD) induced by the potent Schedule II opiate agonist, alfentanil. The first study is a single dose, randomized, double-blind, placebo-controlled, two-period crossover design in sixteen healthy subjects. The primary study objective is to determine if CX717 can prevent RD while preserving the underlying desired analgesic effect of...
Source: Health Business Week (2008-03-21)
|
